Bristol Meyers

Bristol-Meyers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey... 

Peter Shaw Department of Pharmacogenomics and Human Genetics, Bristol-Meyers Squibb, Princeton, New Jersey, U.S. 

Ambarish K. Singh Process Research and Development, The Bristol-Meyers Squibb... 

Abbott Laboratories Acadia Pharmaceuticals Bristol-Meyers Squibb Corcept... 

Research Support Abbott Laboratories Bristol-Meyers Squibb Cyberonics Eli Lilly... 

Bristol-Meyers Squibb (BMS) Press release 16 October 2007. Available at http //www.bms.com/. 

Among the many other non-oxicam-type substances discovered are a sultam pro-drug for potential P3-lactam thrombin inhibitors <1998BML3683>. Furthermore, an anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) pharmacophore based on the 1,2-thiazine structure has also been recently disclosed <1999BML673>. Workers at Bristol-Meyers Squibb have synthesized and evaluated sultam hydroxamates as MMP-2 inhibitors <2004JME2981>. Hydroxamate 38 displayed the best selectivity for MMP-2 over the other proteins in this superfamily of peptidases (Figure 27). As noted in Section 8.07.3.1, an X-ray crystal structure of 38 bound to the protein MMP-13 protein has been solved. 

Mary Noon Doyle, Shepard Chemical Company. Cincinnati, OH, http //www.shepchem.com/. Naphthenic Acids Terrence W. Doyle, Bristol-Meyers Squibb Company. Wallingford. CT. 

Dolatrai M. Vyas. Bristol-Meyers Squibb Company. Wallingford. CT. 

The authors acknowledge the financial support provided by the NIH National Institute of General Medical Sciences, and gifts from Amgen, Lilly, Bristol-Meyers Squibb, Johnson and Johnson, and Merck Research Laboratories. G.L. is grateful to the Swiss National Science Foundation (Stefano Franscini Fond), the Roche Foundation, and the Novartis Foundation for postdoctoral fellowship supports. 

The cell culture process was licensed in May 1995 by Bristol-Meyer Squibb, which in 1998 designated 25 million for development of an FDA-approved commercial process. Many academic and industrial research groups around the world are pursuing plant cell culture routes of production [76-86]. 

Computer network infrastructure should be qualified in support of validated applications. Bristol Meyer Squibb have adopted a three-level model to assist the quahfication of their computer network infrastrucmre. This approach is summarized in Table 14.3. Layer 1 comprises computers that provide shared resources such as servers, hosts, mainframes, and mini computers. Layer 2 is the network infrastrucmre (e g., hubs, routers, and switches). Layer 3 comprises the user desktop environment (i.e., workstations, personal computers, and laptops). 

Bristol-Meyers Company v. United States International Trade Commission, Gema, S. A., Kalipharma, Inc., Purepac Pharmaceutical Co., Istituto Biochimico Italiano Industria Giovanni Lorenzini, Institut Biochimique, S. A., and Biocraft Laboratories, Inc. (Dec. 8,1989)No. 89-1530 [See also United States International Trade Commission, Investigation No. 337-TA-293]. [303]... 

Therapeutic mineral ice gel Bristol-Meyers Menthol liniment... 

Efavirenz/Sustiva Oral Solution/Bristol-Meyers Squibb/HIV... 

Nefazodone.HCI was launched in 1994 in the US and in Canada by Bristol-Meyers Squibb as Serzone for the treatment of depression (Ref. 269). 

Ronald T. Coutts, Faculty of Pharmacy Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada, T6G 2N8 Alekha K. Dash, Department of Pharmaceutical Sciences, School of Pharmacy and Allied Health Professions, Creighton University, Omaha, NE 68178 Hugh Delargy, Bristol-Meyers Squibb Co., Convatec Wound Healing Research Institute, Deeside, U.K. 

Efavirenz/ Sustiva 30 mg/mL Oral Solution/ Bristol-Meyers Squibb/1999 FsC. II ° H FIIV antiviral Adults 600 mg q.d. (up to 20 mF) Pediatrics 270-600 mg (9-20 mF) Oral solution 30 mg/mF Medium-chain triglycerides Benzoic acid Strawberry and Mint flavor RT... 

The same lead structure, sulfisoxazole (11), was also identified by Bristol Meyers Squibb, via the screening hit sulfathiazole (14). In this instance modification of the aniline led, via a naphthalene ring, to the substituted biphenyl 15 " however, preclinical PK studies indicated that the attached isobutyl group was subject to extensive hydroxy-lation. Replacement of this group with an isoxazole ring imparted metabolic stability, and expansion of the SAR at the tolerant 2 -position provided the clinical candidate edo-nentan (16). ... 

---